Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724551 | 0.99 | PARP1 (0.63) | PARP1POLBALOX15SMN1; SMN2PDE7A | |
| SCHEMBL4762105 | 0.97 | PARP1 (0.65) | PARP1POLBALOX15SMN1; SMN2PDE7A | |
| SCHEMBL5523765 | 0.92 | PARP1 (0.59) | PARP1ALOX15SMN1; SMN2PDE7A | |
| SCHEMBL5531967 | 0.92 | PARP1 (0.59) | PARP1PDE7APLAT | |
| SCHEMBL5520213 | 0.89 | PARP1 (0.62) | PARP1ALOX15SMN1; SMN2PLAT | |
| SCHEMBL5526895 | 0.89 | PARP1 (0.62) | PARP1ALOX15SMN1; SMN2 | |
| SCHEMBL5522630 | 0.88 | PARP1 (0.54) | PARP1 | |
| SCHEMBL5517959 | 0.88 | PARP1 (0.54) | PARP1 | |
| SCHEMBL22727814 | 0.87 | PARP1 (0.56) | PARP1PLAT | |
| SCHEMBL5523718 | 0.87 | PARP1 (0.56) | PARP1PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989204-B1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC (US) | 2014-05-21 | — | — | EP | claimed |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-10-25 | — | — | US | claimed |
| EP-2468748-B1 | Pyrazoloquinolones are potent parp inhibitors | ABBVIE INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-1989204-B1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8546368-B2 | Pyrazoloquinolones are potent PARP inhibitors | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2468748-A1 | Pyrazoloquinolones are potent parp inhibitors | Abbott Laboratories (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885POLB 43/4885ALOX15 1857/4885 |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885POLB 43/4885ALOX15 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.